Cybersecurity in Connected Medical Devices: What FDA Now Requires

← Back to All Insights

Connected medical devices represent one of the largest growth vectors in medtech—remote monitoring, wireless drug delivery, cloud-based diagnostics. But they also represent one of the largest and most rapidly evolving regulatory risks. Until recently, FDA cybersecurity guidance was fragmented and reactive. Today, following the PATCH Act (2022) and subsequent FDA guidance (2023), cybersecurity has shifted from a "nice-to-have" engineering concern to a material regulatory requirement with direct implications for FDA clearance, post-market obligations, and investor valuation.

This article breaks down what FDA now requires for connected devices, what this means for portfolio company valuations and timelines, and how cybersecurity vulnerabilities have become a recall and liability vector that most investors haven't yet accounted for.

The FDA's Cybersecurity Evolution

FDA's 2023 Premarket Cybersecurity Guidance represents a fundamental shift. For the first time, cybersecurity is treated as a core design and manufacturing requirement—equivalent to clinical efficacy or biocompatibility. The guidance applies to all networked medical devices (Class II and above), including:

• WiFi/cellular connected devices
• Cloud-based diagnostics and monitoring
• Drug delivery systems with wireless connectivity
• Implantables with remote interrogation capability
• Devices using wireless communication for data transfer

For PE/VC investors, this creates three critical risk categories: premarket compliance (FDA won't clear your device if cybersecurity is inadequate), post-market obligations (FDA can mandate security updates after approval), and liability exposure (recalls and consent decrees for cybersecurity failures).

The Five Core FDA Cybersecurity Requirements

1. Threat Modeling and Risk Assessment

FDA expects companies to document a formal threat model: what are the potential cybersecurity vulnerabilities in your device, and what's the risk if those vulnerabilities are exploited? This isn't a checklist—it's a structured analysis using methodologies like STRIDE, attack trees, or NIST frameworks.

For example: A wireless insulin pump must identify threats such as unauthorized wireless command injection, firmware modification, patient data interception, and cloud server compromise. For each threat, the company must specify the potential harm (incorrect insulin delivery, leading to hypoglycemia or hyperglycemia) and the mitigation (encrypted communication, firmware signing, authentication protocols).

Red flag: Companies that identify threats but don't document mitigations or can't quantify residual risk. FDA will ask: "How do you know your mitigations work?"

2. Software Bill of Materials (SBOM)

Every connected device has software—whether it's a microcontroller firmware, cloud backend, mobile app, or all three. FDA now requires a comprehensive SBOM documenting every software component, library, and dependency. This includes:

• Third-party libraries (e.g., OpenSSL, Apache, Node.js libraries)
• Open-source components with known vulnerabilities
• Proprietary code modules
• Version numbers and patch status

Why? Because vulnerabilities in third-party code (like the Log4j vulnerability in 2021) can compromise your entire device. FDA wants to know: "If a critical vulnerability is discovered in a library you're using, can you rapidly patch it?"

Real example: A remote cardiac monitoring startup used an old version of a popular IoT library with a known authentication bypass vulnerability. The vulnerability was disclosed 18 months before their FDA submission. FDA's position: "You're submitting with a known vulnerability in your device? How is this cleared for patient use?" The company had to redesign, upgrade dependencies, and revalidate—adding 8 months to timeline.

3. Coordinated Vulnerability Disclosure and Patch Management

FDA expects companies to have a documented process for handling vulnerability reports. If a security researcher (or malicious actor) discovers a vulnerability in your device, what's your response protocol?

The FDA 2023 guidance specifies:

• Vulnerability intake: A publicly documented email or process for responsible researchers to report vulnerabilities
• Triage and response timeline: How quickly you'll assess severity and determine mitigation strategy
• Patch development and testing: Process for developing, validating, and releasing patches
• Patient notification: If a vulnerability poses patient harm, how you'll notify healthcare providers and patients

Critical vulnerabilities (those posing imminent harm) should have patches within weeks, not months. Moderate vulnerabilities typically require patches within 90 days.

4. Authentication, Encryption, and Secure Configuration

FDA expects industry-standard security controls:

• Authentication: Only authorized users/devices can access the device or modify settings (not default credentials, not hardcoded passwords)
• Encryption: Data in transit (wireless communication) and at rest (cloud storage) must be encrypted using validated algorithms (AES-256, TLS 1.2+)
• Secure configuration: Devices ship with security enabled by default, not disabled for "ease of use"
• Key management: If your device uses cryptographic keys, how are they generated, stored, and rotated?

This seems basic, but we regularly see devices with plaintext data transmission, hardcoded credentials, or wireless protocols with no encryption. FDA will require remediation.

5. Post-Market Cybersecurity Management

FDA doesn't expect perfect security forever—they expect active post-market monitoring and response. This means:

• Vulnerability monitoring: Ongoing assessment of third-party dependencies for known vulnerabilities
• Security updates: Plan for periodic firmware or software updates to address newly discovered vulnerabilities
• End-of-life support: When you discontinue the device, when do you stop providing security patches? (FDA expects at least 5-7 years for critical devices)
• Transparency: Public disclosure of vulnerabilities, patches, and security advisories

Companies building connected devices need to budget for post-market cybersecurity. This isn't a one-time engineering project; it's an ongoing operational commitment.

Real-World Impact: Cybersecurity Recalls and Regulatory Action

Cybersecurity failures are now triggering FDA recalls and Class I (most serious) regulatory actions:

• Medtronic Insulin Pump (2018-2019): Multiple vulnerability disclosures led to FDA warning letters and emergency patches. Devices still recalled if not updated.
• Philips Respironics (2021): FDA warning letter for "serious deficiencies" in cybersecurity controls, including outdated firmware components with known vulnerabilities.
• GE HealthCare (2022): Authentication bypass vulnerability in medical imaging devices led to FDA cybersecurity advisory and mandatory patches.

For investors: cybersecurity vulnerabilities discovered post-market can trigger recalls (costly), FDA warning letters (regulatory credibility damage), and litigation liability (patients harmed by exploited vulnerabilities). This is material financial risk that most VC/PE investment theses haven't properly accounted for.

Implications for Device Companies and Investors

For Founders Building Connected Devices

Cybersecurity isn't a checkbox item for post-clearance—it's a premarket gating requirement. Your timeline and budget should include:

• Threat modeling workshops (2-3 months)
• Security code review and penetration testing ($50-150K)
• SBOM generation and dependency auditing (1-2 months)
• FDA pre-submission meeting specifically discussing cybersecurity strategy (included free, but plan for 3-4 month lead time)
• Post-market security update infrastructure ($100-300K development)

Total estimated budget: $300-500K. Total timeline impact: 6-9 additional months if you haven't already integrated cybersecurity into design.

For Investors Evaluating Portfolio Companies

Cybersecurity is now a due diligence category equivalent to clinical efficacy and manufacturing readiness. Key assessment questions:

• Does the device have wireless connectivity? If yes, has formal threat modeling been completed?
• Is there a documented SBOM? Can you trace every third-party dependency?
• Are cryptographic controls implemented (encryption, authentication) using validated standards?
• Is there a vulnerability disclosure process and patch management timeline?
• Has the company budgeted for post-market security updates and long-term support?

Companies scoring poorly on these questions face 6-12 month FDA delays and $500K-$2M in unexpected remediation costs. This should factor directly into valuation multiples and exit timing assumptions.

How Vantage Evaluates Cybersecurity Risk

Within our proprietary framework, cybersecurity spans two critical assessment areas:

1. Technology & IP (Category 3): Software architecture, dependency management, cryptographic controls
2. Regulatory & Compliance (Category 2): Threat modeling, SBOM completeness, FDA cybersecurity strategy, post-market management plan

We score each dimension, synthesizing into a cybersecurity risk rating. Companies scoring "Green" have formal threat models, documented SBOMs, and explicit FDA cybersecurity strategies. Companies scoring "Yellow" have some cybersecurity consideration but gaps in threat modeling or patch management. Companies scoring "Red" lack basic cybersecurity controls or haven't integrated cybersecurity into their regulatory strategy.

The Bottom Line

Cybersecurity for connected medical devices is no longer optional or deferrable. FDA treats it as a core regulatory requirement, equivalent to clinical efficacy. Companies and investors that ignore cybersecurity face regulatory delays, unexpected remediation costs, and post-market liability exposure that can destroy valuations. The best time to integrate cybersecurity is during device design, not after FDA raises questions.

"The cost of fixing cybersecurity after regulatory review is 10x the cost of fixing it before submission."

Need a Custom Analysis?

Our proprietary risk framework has been validated against documented medical device companies. Get a complimentary cybersecurity readiness assessment for your connected device portfolio.

Schedule Free Discovery Call Download Free Red Flags Guide